Jacek Capala

List of Publications by Year
in descending order

50 papers	1,954 citations	218677 26 h-index	243625 44 g-index
54 all docs	54 docs citations	54 times ranked	2887 citing authors

#	Article	IF	Citations
1	Affibody Molecules for <i>In vivo</i> Characterization of HER2-Positive Tumors by Near-Infrared Imaging. Clinical Cancer Research, 2008, 14, 3840-3849.	7.0	164
2	[18F]FBEM-ZHER2:342-Affibody moleculeâ€"a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1008-1018.	6.4	137
3	Changes in<i>HER2</i>Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and¹⁸F-Labeled Affibody Molecules. Journal of Nuclear Medicine, 2009, 50, 1131-1139.	5.0	96
4	HER2-Specific Affibody-Conjugated Thermosensitive Liposomes (Affisomes) for Improved Delivery of Anticancer Agents. Journal of Liposome Research, 2008, 18, 293-307.	3.3	95
5	Molecular imaging of HER2-positive breast cancer: a step toward an individualized â€˜image and treatâ€™ strategy. Current Opinion in Oncology, 2010, 22, 559-566.	2.4	95
6	Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. Discovery Medicine, 2010, 9, 55-61.	0.5	91
7	PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Seminars in Nuclear Medicine, 2011, 41, 29-44.	4.6	84
8	Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles. Theranostics, 2019, 9, 778-795.	10.0	82
9	Hyperthermia-triggered intracellular delivery of anticancer agent to HER2+ cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2+ affisomes). Journal of Controlled Release, 2011, 153, 187-194.	9.9	75
10	ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget, 2014, 5, 6633-6646.	1.8	66
11	Affitoxinâ€"A Novel Recombinant, HER2-specific, Anticancer Agent for Targeted Therapy of HER2-positive Tumors. Journal of Immunotherapy, 2009, 32, 817-825.	2.4	63
12	Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget, 2014, 5, 5934-5949.	1.8	59
13	68Ga-DOTA-Affibody molecule for in vivo assessment of HER2/neu expression with PET. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1967-1976.	6.4	48
14	Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations. Translational Oncology, 2016, 9, 46-56.	3.7	48
15	HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors. Clinical Cancer Research, 2011, 17, 5071-5081.	7.0	46
16	Current Status of Radiopharmaceutical Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 109, 891-901.	0.8	44
17	Targeted Radionuclide Therapy: Practical Applications and Future Prospects. Biomarkers in Cancer, 2016, 8s2, BIC.S31804.	3.6	42
18	Radiolabeling of HER2-specific AffibodyÂ® molecule with F-18. Journal of Fluorine Chemistry, 2008, 129, 799-806.	1.7	37

#	Article	IF	Citations
19	HER2â€•and EGFRâ€Specific Affiprobes: Novel Recombinant Optical Probes for Cell Imaging. ChemBioChem, 2010, 11, 345-350.	2.6	35
20	â€˜Image and treatâ€™: an individualized approach to urological tumors. Current Opinion in Oncology, 2010, 22, 274-280.	2.4	33
21	In Vivo Fluorescence Lifetime Imaging Monitors Binding of Specific Probes to Cancer Biomarkers. PLoS ONE, 2012, 7, e31881.	2.5	33
22	The role of nuclear medicine in modern therapy of cancer. Tumor Biology, 2012, 33, 629-640.	1.8	32
23	Using In-Vivo Fluorescence Imaging in Personalized Cancer Diagnostics and Therapy, an Image and Treat Paradigm. Technology in Cancer Research and Treatment, 2011, 10, 549-560.	1.9	31
24	Quantitative Analysis of HER2 Receptor Expression In Vivo by Near-Infrared Optical Imaging. Molecular Imaging, 2010, 9, 7290.2010.00018.	1.4	29
25	PET of HER2-Positive Pulmonary Metastases with ¹⁸F-Z_{HER2:342} Affibody in a Murine Model of Breast Cancer: Comparison with ¹⁸F-FDG. Journal of Nuclear Medicine, 2012, 53, 939-946.	5.0	29
26	Overview of the American Society for Radiation Oncologyâ€“National Institutes of Healthâ€“American Association of Physicists in Medicine Workshop 2015: Exploring Opportunities for Radiation Oncology in the Era of Big Data. International Journal of Radiation Oncology Biology Physics, 2016, 95, 873-879.	0.8	27
27	Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer. Current Opinion in Oncology, 2009, 21, 469-474.	2.4	26
28	Accuracy of 3D volumetric image registration based on CT, MR and PET/CT phantom experiments. Journal of Applied Clinical Medical Physics, 2008, 9, 17-36.	1.9	25
29	How Will Big Data Improve Clinical and Basic Research in Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 895-904.	0.8	25
30	Effects of131I-EGF on cultured human glioma cells. Journal of Neuro-Oncology, 1990, 9, 201-210.	2.9	23
31	Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. Molecular Imaging, 2010, 9, 192-200.	1.4	22
32	Polylactide-Based Paclitaxel-Loaded Nanoparticles Fabricated by Dispersion Polymerization: Characterization, Evaluation in Cancer Cell Lines, and Preliminary Biodistribution Studies. Journal of Pharmaceutical Sciences, 2014, 103, 2546-2555.	3.3	21
33	Affibody-DyLight Conjugates for In Vivo Assessment of HER2 Expression by Near-Infrared Optical Imaging. PLoS ONE, 2012, 7, e41016.	2.5	19
34	Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Molecular Biology Reports, 2011, 38, 4237-4243.	2.3	18
35	Imaging and Data Acquisition in Clinical Trials for Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 94, 404-411.	0.8	17
36	In Vivo Method to Monitor Changes in HER2 Expression Using Near-Infrared Fluorescence Imaging. Molecular Imaging, 2012, 11, 7290.2011.00038.	1.4	13

#	Article	IF	Citations
37	Accurate, Precision Radiation Medicine: A Meta-Strategy for Impacting Cancer Care, Global Health, and Nuclear Policy and Mitigating Radiation Injury From Necessary Medical Use, Space Exploration, and Potential Terrorism. International Journal of Radiation Oncology Biology Physics, 2018, 101, 250-253.	0.8	13
38	Advancing Targeted Radionuclide Therapy Through the National Cancer Instituteâ€™s Small Business Innovation Research Pathway. Journal of Nuclear Medicine, 2019, 60, 41-49.	5.0	10
39	In vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging. Molecular Imaging, 2012, 11, 177-86.	1.4	9
40	Phase 0 Radiopharmaceuticalâ€"Agent Clinical Development. Frontiers in Oncology, 2020, 10, 1310.	2.8	8
41	Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care. JNCI Cancer Spectrum, 2021, 5, pkab046.	2.9	6
42	Overview of the First NRG Oncologyâ€"National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 2021, 62, 1133-1139.	5.0	5
43	Toward Individualized Voxel-Level Dosimetry for Radiopharmaceutical Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 109, 902-904.	0.8	5
44	In Vivo Assessment of HER2 Receptor Density in HER2-positive Tumors by Near-infrared Imaging, Using Repeated Injections of the Fluorescent Probe. TCRT Express, 2014, 13, 427-34.	1.5	4
45	Medical use of all high activity sources should be eliminated for security concerns. Medical Physics, 2015, 42, 6773-6775.	3.0	4
46	Registering Molecular Imaging Information into Anatomic Images with Improved Spatial Accuracy. , 2007, , .		3
47	National Cancer Institute support for targeted alpha-emitter therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 64-72.	6.4	3
48	A New Generation of â€œMagic Bulletsâ€•for Molecular Targeting of Cancer. Clinical Cancer Research, 2021, 27, 377-379.	7.0	2
49	Tumor Heterogeneity Research and Innovation in Biologically Based Radiation Therapy From the National Cancer Institute Radiation Research Program Portfolio. Journal of Clinical Oncology, 2022, 40, 1861-1869.	1.6	1
50	Response to â€œComment on â€˜Medical use of all high activity sources should be eliminated for security concernsâ€™â€‰â€•[Med. Phys. 42, 6773â€"6775 (2015)]. Medical Physics, 2016, 43, 4461-4461.	3.0	0